[go: up one dir, main page]

CN107207532A - 抗肺结核病的硝基咪唑衍生物 - Google Patents

抗肺结核病的硝基咪唑衍生物 Download PDF

Info

Publication number
CN107207532A
CN107207532A CN201680006991.1A CN201680006991A CN107207532A CN 107207532 A CN107207532 A CN 107207532A CN 201680006991 A CN201680006991 A CN 201680006991A CN 107207532 A CN107207532 A CN 107207532A
Authority
CN
China
Prior art keywords
methyl
milliliters
milligrams
equivalents
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680006991.1A
Other languages
English (en)
Other versions
CN107207532B (zh
Inventor
罗微
丁照中
黄志刚
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Jiabao Pharmaceutical Silver Pharmaceutical Technology Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610006632.8A external-priority patent/CN106946909A/zh
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN107207532A publication Critical patent/CN107207532A/zh
Application granted granted Critical
Publication of CN107207532B publication Critical patent/CN107207532B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明公开了一种取代硝基咪唑类衍生物，其主要用于治疗由分支杆菌感染引起的相关疾病，如结核分枝杆菌，尤其适用于耐药性结核分支杆菌引起的疾病。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201680006991.1A 2015-01-29 2016-01-28 抗肺结核病的硝基咪唑衍生物 Active CN107207532B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510048040 2015-01-29
CN2015100480408 2015-01-29
CN2016100066328 2016-01-06
CN201610006632.8A CN106946909A (zh) 2016-01-06 2016-01-06 抗肺结核病的硝基咪唑衍生物
PCT/CN2016/072447 WO2016119706A1 (zh) 2015-01-29 2016-01-28 抗肺结核病的硝基咪唑衍生物

Publications (2)

Publication Number Publication Date
CN107207532A true CN107207532A (zh) 2017-09-26
CN107207532B CN107207532B (zh) 2019-07-30

Family

ID=56542438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680006991.1A Active CN107207532B (zh) 2015-01-29 2016-01-28 抗肺结核病的硝基咪唑衍生物

Country Status (10)

Country Link
US (1) US10227362B2 (zh)
EP (1) EP3252059A4 (zh)
JP (1) JP6542900B2 (zh)
CN (1) CN107207532B (zh)
BR (1) BR112017015744A2 (zh)
MX (1) MX2017009810A (zh)
RU (1) RU2675622C1 (zh)
TW (1) TW201632533A (zh)
WO (1) WO2016119706A1 (zh)
ZA (1) ZA201705362B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109496214A (zh) * 2016-07-22 2019-03-19 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10971760B2 (en) 2018-01-31 2021-04-06 Keracel, Inc. Hybrid solid-state cell with a sealed anode structure
JP7530384B2 (ja) * 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
AR127948A1 (es) 2021-12-14 2024-03-13 Boehringer Ingelheim Int Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica
WO2023237580A1 (en) * 2022-06-07 2023-12-14 Institut National De La Sante Et De La Recherche Medicale Tricyclic spirolactam compounds with antimycobacterial activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705670A (zh) * 2002-10-11 2005-12-07 大塚制药株式会社 2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
CN1878777A (zh) * 2003-10-31 2006-12-13 大塚制药株式会社 治疗结核病的2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
CN103596960A (zh) * 2011-04-15 2014-02-19 大塚制药株式会社 6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
US6087358A (en) 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
ES2314460T3 (es) * 2003-10-31 2009-03-16 Otsuka Pharmaceutical Co., Ltd. Compuestos de 2,3-dihidro-6-nitroimidazo (2,1-b)oxazol para el tratamiento de la tuberculosis.
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
US20080275035A1 (en) 2005-12-23 2008-11-06 Jan Jiricek Nitroimidazole Compounds
US7678791B2 (en) 2006-07-12 2010-03-16 Cumbre Ip Ventures, L.P. Nitroheteroaryl-containing rifamycin derivatives
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
US7666864B2 (en) 2008-03-26 2010-02-23 Global Alliance For Tb Drug Development Bicyclic nitroimidazole-substituted phenyl oxazolidinones
AU2010278779B2 (en) 2009-07-31 2014-08-14 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
CA2769359C (en) 2009-07-31 2017-03-07 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011087995A2 (en) 2010-01-13 2011-07-21 Clifton Barry Organic compounds
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
WO2013072903A1 (en) 2011-11-17 2013-05-23 Ithemba Pharmaceuticals (Proprietary) Limited Nitroimidazoxadiazocine compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705670A (zh) * 2002-10-11 2005-12-07 大塚制药株式会社 2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
CN1878777A (zh) * 2003-10-31 2006-12-13 大塚制药株式会社 治疗结核病的2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
CN103596960A (zh) * 2011-04-15 2014-02-19 大塚制药株式会社 6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109496214A (zh) * 2016-07-22 2019-03-19 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法
CN109496214B (zh) * 2016-07-22 2024-09-10 成都嘉葆药银医药科技有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Also Published As

Publication number Publication date
EP3252059A4 (en) 2018-07-11
US20180162878A1 (en) 2018-06-14
ZA201705362B (en) 2019-06-26
US10227362B2 (en) 2019-03-12
MX2017009810A (es) 2018-11-09
JP6542900B2 (ja) 2019-07-10
CN107207532B (zh) 2019-07-30
WO2016119706A1 (zh) 2016-08-04
RU2675622C1 (ru) 2018-12-21
JP2018503658A (ja) 2018-02-08
EP3252059A1 (en) 2017-12-06
TW201632533A (zh) 2016-09-16
BR112017015744A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
CA3002542C (en) Substituted azepin heterocyclic derivatives and compositions thereof useful as rip1 kinase inhibitor
EP3670506B1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
JP5816353B2 (ja) 新規ピラゾール誘導体
CA3156777A1 (en) Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
EP4585599A1 (en) Nitrogen-containing fused ring compound, intermediate thereof, preparation method therefor and use thereof
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
JP2018521025A (ja) Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体
CN107207532A (zh) 抗肺结核病的硝基咪唑衍生物
AU2018334272A1 (en) Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors
AU2020380828A1 (en) WDR5 inhibitors and modulators
AU2023279857A1 (en) Novel par-2 inhibitors
IL298397A (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
CN106946909A (zh) 抗肺结核病的硝基咪唑衍生物
CN120936610A (zh) 可用于治疗神经障碍和精神障碍的作为毒蕈碱型乙酰胆碱受体m4正向别构调节剂的1,6-萘啶衍生物
HK40093304A (zh) 用作pim激酶抑制剂的吡啶甲醯胺化合物
EA039704B1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
HK1216424B (zh) 可用作pim激酶抑制劑的噻唑甲醯胺和吡啶甲醯胺化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Patentee after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Patentee before: MEDSHINE DISCOVERY Inc.

CP01 Change in the name or title of a patent holder
TR01 Transfer of patent right

Effective date of registration: 20191101

Address after: 518053 2201-6, building a, wisdom Plaza, Nanshan District, Shenzhen City, Guangdong Province

Patentee after: Shenzhen Huayi Biotechnology Group Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200107

Address after: 610000 No.18, Section 2, bio Chengzhong Road, Chengdu hi tech Zone, Chengdu, Sichuan Province

Patentee after: Chengdu Jiabao pharmaceutical silver Pharmaceutical Technology Co.,Ltd.

Address before: 518053 2201-6, building a, wisdom Plaza, Nanshan District, Shenzhen City, Guangdong Province

Patentee before: Shenzhen Huayi Biotechnology Group Co.,Ltd.

TR01 Transfer of patent right